BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/19/2021 11:15:33 AM | Browse: 660 | Download: 1484
 |
Received |
|
2021-04-23 04:58 |
|
Peer-Review Started |
|
2021-04-23 05:01 |
|
First Decision by Editorial Office Director |
|
2021-06-13 13:29 |
|
Return for Revision |
|
2021-06-13 13:29 |
|
Revised |
|
2021-07-31 06:20 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-10-29 09:57 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-10-31 18:12 |
|
Articles in Press |
|
2021-10-31 18:12 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-11-16 14:43 |
|
Publish the Manuscript Online |
|
2021-11-19 11:15 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Miwa Kawanaka, Ken Nishino, Hirofumi Kawamoto and Ken Haruma |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Miwa Kawanaka, MD, PhD, Associate Professor, Doctor, Doctor, Department of General Internal Medicine 2, General Medical Center, Kawasaki Medical School, 2-6-1 Nakasange, Kita-ku, Okayama 700-8505, Japan. m.kawanaka@med.kawasaki-m.ac.jp |
| Key Words |
Hepatitis B; Immune tolerance; Immune-inactive; Anti-viral therapy; Hepatocellular carcinoma; Cirrhosis |
| Core Tip |
Hepatitis B virus (HBV) is a global health problem that causes acute and chronic infections and often leads to liver cirrhosis and hepatocellular carcinoma. Treatment of HBV is recommended for patients in the immunoactive hepatitis B surface-antigen-positive and -negative phases. Follow-up is recommended only for patients in the immune-inactive phase and the immune-tolerant phase, but opinion on this recommendation remain divided. This review discusses the major international guidelines for the treatment of chronic hepatitis B and highlights the importance of clinical factors for making decisions regarding the management of patients with HBV infection. |
| Publish Date |
2021-11-19 11:15 |
| Citation |
Kawanaka M, Nishino K, Kawamoto H, Haruma K. Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases. World J Gastroenterol 2021; 27(43): 7497-7508 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i43/7497.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i43.7497 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
